#arexvy — Public Fediverse posts

How do #vaccines reduce the risk of #dementia? | https://www.ox.ac.uk/news/2025-06-25-how-do-vaccines-reduce-risk-dementia “#Arexvy, now offered to adults over 60, contains the same adjuvant as Shingrix. Both vaccines were similarly effective in reducing dementia risk compared to the flu vaccine (which does not contain the adjuvant); in the 18 months following receipt of Arexvy there was a 29% reduction in diagnoses of dementia. These findings held true across a range of additional analyses and were similar in men and women.”

I just got the newly-released #Arexvy RSV vaccine at CVSHealth (I have history of asthma with viral infections, and I'm no longer 18). So, now protected for RSV, Flu, and Covid-19, the triple threat this year. SCIENCE! @Sci_Furs

The Commission has authorised #Arexvy, the 1st vaccine to protect adults aged 60 years +, against the respiratory syncytial virus RSV.

“I encourage Member States to build on this authorisation so that those most at risk can access them in the coming months” @SKyriakidesEU

🐦🔗: https://n.respublicae.eu/EUCYPRUS/status/1666049150746611713

For 60 years, doctors and scientists searched for a vaccine against a common virus that, while sometimes deadly, is little known to the public. Now the hunt is over. https://www.japantimes.co.jp/news/2023/05/04/world/science-health-world/first-rsv-vaccine-pervasive-lung-illness/?utm_content=bufferb5b1f&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #worldnews #vaccines #pharmaceuticals #gsk #rsv #arexvy

US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

GSK plc (LSE/NYSE: GSK) today announced that the #FDA has approved #AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (#RSV) in individuals 60 years of age and older.

#Healthcare #Seniors
https://apnews.com/54ab6336198c4fe68d5988f6edb1a1d6